29Feb 2024
Study Reveals LRG-1 as Prognostic Biomarker in Early Breast Cancer Patients

Study Reveals LRG-1 as Prognostic Biomarker in Early Breast Cancer Patients

A study evaluated serum levels of leucine-rich α-2 glycoprotein 1 (LRG-1) in 509 patients with early breast cancer (BC), investigating its correlation with disseminated tumour cells (DTCs) in the bone marrow and survival outcomes. Findings revealed mean serum LRG-1 levels of 29.70 ± 8.67 µg/ml, with higher levels observed in older and postmenopausal patients. Patients lacking DTCs displayed significantly elevated LRG-1 levels. High serum LRG-1 levels were associated with lower overall and BC-specific survival rates. Multivariate analysis identified LRG-1 as an independent prognostic marker for BC-specific survival. This study highlights LRG-1's potential as a predictive biomarker in early BC.

  • #gynaecology - ivf

Like

Save

Share